KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Interest Expenses (2020 - 2025)

Alnylam Pharmaceuticals' Interest Expenses history spans 6 years, with the latest figure at $65.4 million for Q4 2025.

  • For Q4 2025, Interest Expenses rose 67.82% year-over-year to $65.4 million; the TTM value through Dec 2025 reached $208.4 million, up 46.87%, while the annual FY2025 figure was $252.6 million, 78.08% up from the prior year.
  • Interest Expenses reached $65.4 million in Q4 2025 per ALNY's latest filing, up from $44.4 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $65.4 million in Q4 2025 to a low of $29.0 million in Q1 2023.
  • Average Interest Expenses over 5 years is $38.5 million, with a median of $36.0 million recorded in 2021.
  • Peak YoY movement for Interest Expenses: tumbled 31.65% in 2023, then skyrocketed 67.82% in 2025.
  • A 5-year view of Interest Expenses shows it stood at $36.8 million in 2021, then decreased by 18.75% to $29.9 million in 2022, then rose by 4.76% to $31.3 million in 2023, then grew by 24.36% to $39.0 million in 2024, then skyrocketed by 67.82% to $65.4 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Interest Expenses are $65.4 million (Q4 2025), $44.4 million (Q3 2025), and $40.2 million (Q2 2025).